Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.67 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.64 |
| ▸ | RARA | P10276 | 1/20 | 0.56 |
| ▸ | RARB | P10826 | 1/20 | 0.56 |
| ▸ | RARG | P13631 | 1/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659598 | 1.00 | MAPK14 (0.67) | MAPK14MAPK11RARARARBRARG | |
| SCHEMBL5122607 | 0.92 | MAPK14 (0.60) | MAPK14MAPK11RARARARBRARG | |
| SCHEMBL6655856 | 0.89 | MAPK14 (0.61) | MAPK14MAPK11RARARARBRARG | |
| SCHEMBL7448719 | 0.89 | MAPK14 (0.57) | MAPK14MAPK11RARARARBRARG | |
| SCHEMBL4860601 | 0.88 | MAPK14 (0.65) | MAPK14MAPK11MAP2K1 | |
| SCHEMBL5123466 | 0.85 | MAPK14 (0.72) | MAPK14MAPK11RARARARBRARG | |
| SCHEMBL4861254 | 0.85 | MAPK14 (0.67) | MAPK14MAPK11MAP2K1 | |
| SCHEMBL4865916 | 0.85 | MAPK14 (0.67) | MAPK14MAPK11MAP2K1 | |
| SCHEMBL4860460 | 0.85 | MAPK14 (0.63) | MAPK14MAPK11MAP2K1 | |
| SCHEMBL70030 | 0.85 | NPC1 (0.69) | MAPK14RARARARBRARGNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384963-B2 | 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase | GLAXO GROUP LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-20070112046-A1 | 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-17 | — | — | US | disclosed |
| US-7166623-B2 | 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20050090491-A1 | 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| EP-1435950-A1 | 2'-METHYL-5'-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435949-A1 | 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| EP-1436269-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032986-A1 | 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003033482-A1 | OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003032987-A1 | 2'-METHYL-5'-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| EP-0799226-B1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-02-07 | — | — | EP | disclosed |
| US-5972951-A | Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-10-26 | — | — | US | disclosed |
| WO-1996019477-A1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112046-A1 | 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors | MAPK1, MAPK3, MAPKAPK2 | MAPK14 7/4885MAPK11 36/4885RARA 2603/4885 |
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | MAPK1, MAPK3, MAPK6 | MAPK14 11/4885MAPK11 17/4885RARA 2744/4885 |
| US-20050090491-A1 | 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GRK4, MAPK4, MAPK1 | MAPK14 19/4885MAPK11 64/4885RARA 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.